Cerebrolysin Dosage: Trial Data and Why There Is No Common Protocol
Cerebrolysin dosage: the IV doses published trials actually used, by indication - and why grey-market vendor guides disagree too much to state a common protocol.
The short version
Cerebrolysin has no approved dose. Unlike most research peptides on this site, it also has no usable "common practice" protocol, because the vendor dosing guides I checked disagree on route, dose and even the unit. Published trials gave a clinician-administered IV infusion. Stroke rehabilitation got 30 mL a day for 21 days. Vascular dementia got roughly 10-30 mL a day in courses repeated over months. One vendor guide gives 10-50 mL a day over 10-21 day courses.
- No common self-administered protocol could be established: two vendor sources disagreed on route, dose and unit.
- Published trials used clinician-administered IV infusion, not a self-injected vial protocol.
- The stroke-recovery trial used 30 mL IV once daily for 21 days, started 24-72 hours after stroke onset.
- The dementia trial evidence covers a range of 10-30 mL IV daily, in courses repeated over months.
Cerebrolysin has no approved dose, because it has no FDA-approved product. Unlike most research compounds on this site, it also has no sourced “common protocol”. The reason is below. For what it is and what the trial evidence shows overall, see the main Cerebrolysin guide.
US legal status - Unapproved drug
No FDA-approved product exists. DailyMed lists no US drug label for cerebrolysin.
AU legal status - Not on the ARTG
Not on the Australian Register of Therapeutic Goods (TGA).
Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.
Cerebrolysin dosage: why there is no common protocol
This site states a common practice protocol only when at least two real sources, on different sites, agree on usable numbers. For cerebrolysin they did not. I fetched and read two vendor dosing guides in full:
| Source | Route described | Dose described |
|---|---|---|
| MyPeptideMatch | IV (its “evidence-based” course) and, separately, subcutaneous | IV: 30 mL/day x10 days. SC: 60 mg/week, labelled by the source itself as off-label extrapolation |
| TrimRx | IV infusion or intramuscular injection only | 10-50 mL/day depending on indication, over 10-21 day courses; no subcutaneous protocol mentioned at all |
The two disagree on three points:
- Route. One describes subcutaneous dosing. The other does not mention it.
- Unit. Milligrams of peptide versus millilitres of solution. These are not directly convertible without the exact product’s concentration.
- Magnitude.
Averaging incompatible numbers into one figure would manufacture a false consensus, so this page reports the published trial doses instead.
Cerebrolysin doses used in human trials
| Trial / indication | Dose | Route | Schedule |
|---|---|---|---|
| Early stroke rehabilitation Muresanu 2016 - Muresanu DF, Heiss WD, Hoemberg V et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-9., in the references below | 30 mL | IV infusion | Once daily for 21 days, starting 24-72 hours after stroke onset |
| Vascular dementia trials reviewed by Cochrane Cui 2019 - Cui S, Chen N, Yang M et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11)., in the references below | Roughly 10-30 mL | IV infusion | Daily, in courses repeated over multiple months |
| Acute ischaemic stroke trials reviewed by Cochrane Ziganshina 2023 - Ziganshina LE, Abakumova T, Nurkhametova D et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026., in the references below | Varied by trial across the reviewed set | IV infusion | Daily courses; the review itself does not reduce these to one figure |
The stroke rehabilitation trial reported a benefit on motor function and global outcome at its 30 mL/day, 21-day protocol, and described the result as exploratory Muresanu 2016 - Muresanu DF, Heiss WD, Hoemberg V et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-9., in the references below.
The Cochrane review of acute ischaemic stroke covered 7 trials at various doses within this range. It found no benefit on preventing death and a probable increase in non-fatal serious adverse events. A dose appearing in this table is therefore not a dose Cochrane’s own synthesis endorses Ziganshina 2023 - Ziganshina LE, Abakumova T, Nurkhametova D et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026., in the references below.
What is not established
- No dose has been shown safe or effective for self-administration. Every figure above is a clinician-delivered hospital protocol, in a monitored patient population being treated for a specific diagnosed condition.
- No FDA-approved product or dose exists in the United States.
- Vendor “common protocol” claims for this compound do not hold up. See the disagreement table above.
- Intramuscular dosing, mentioned by one vendor source for smaller volumes, has no published human pharmacokinetic or dosing trial behind it that this page could verify.
Who should not use it
No FDA-reviewed contraindication list exists, because no US review has happened. The trials cited here enrolled hospitalised patients with a specific diagnosed condition (acute stroke, vascular dementia) under close clinical monitoring. They excluded people with unrelated significant medical conditions. That shows who a monitored trial considered eligible. It is not a safety clearance for self-administration by anyone else, especially outside a hospital.
Cerebrolysin side effects and risks
Cochrane’s 2023 review of the acute ischaemic stroke evidence covered 7 randomised trials. It reported that cerebrolysin probably increases the number of people who have a non-fatal serious adverse event, without reducing deaths Ziganshina 2023 - Ziganshina LE, Abakumova T, Nurkhametova D et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026., in the references below. That is the highest-quality available synthesis for the indication it is most marketed for.
Cerebrolysin is also a porcine-tissue-derived biological extract. That carries hypersensitivity and batch-variation risks that a synthesised, sequence-defined research peptide does not. A vial bought outside its approved markets from a grey-market vendor has no verified content, sterility or actual concentration.
Related
- Cerebrolysin: what it is and what the research shows
- Research peptides and the law
- Are peptides safe?
Where to buy Cerebrolysin for research
Each vendor is checked against my vendor checklist.
1.Next Level PharmFeatured
60 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
2.BioEdge Research Labs
30 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
Common questions
What is the usual Cerebrolysin dose?
No regulator has established a dose, and this site could not establish a common self-administered protocol. Two vendor dosing guides, checked on different sites, disagreed on route, dose and unit. One described an off-label subcutaneous protocol in milligrams. The other described only IV or intramuscular dosing in millilitres of solution, 10-50 mL per day over 10-21 day courses. Published clinical trials used a clinician-administered IV infusion. See the trial table below.
What dose did the stroke rehabilitation trial use?
A randomised, placebo-controlled trial in early stroke rehabilitation gave cerebrolysin as 30 mL by IV infusion once daily for 21 days, starting 24 to 72 hours after stroke onset. That is one trial protocol in a monitored hospital setting, not a recommended dose for anyone outside it.
What dose did the dementia trials use?
The 2019 Cochrane review of cerebrolysin for vascular dementia reports the trials used daily IV doses of roughly 10-30 mL, in courses repeated over multiple months. That is a lower per-day amount than the acute-stroke trials, consistent with a chronic rather than acute-injury use case.
Why is there no common protocol on this page, when other research compounds get one?
This site reports a common protocol only when at least two real sources, on different sites, agree on usable numbers. For cerebrolysin they did not. The two vendor dosing pages I fetched described different routes (subcutaneous versus IV/IM), different units (milligrams of peptide versus millilitres of solution) and materially different magnitudes. One labelled its own protocol as off-label extrapolation. Rather than average incompatible numbers into a false consensus, this page reports what the published trials used.
Is there an FDA-approved Cerebrolysin dose?
No. Cerebrolysin has no FDA-approved product in the United States, and DailyMed lists no US drug label for it. It is a real prescription drug in Russia, China and other markets, dosed there by clinicians. That is not an FDA-reviewed dose.
What are the main risks?
Cochrane's 2023 review of the acute-stroke evidence reported that cerebrolysin probably increases the number of people with a non-fatal serious adverse event, without reducing deaths. It is also a porcine-tissue-derived biological extract with batch-to-batch variation. It is sold outside its approved markets through unregulated vendors, with no verified content or sterility.
When should I stop and get medical care?
Get emergency care (call 911 in the US) for signs of a severe allergic reaction, such as swelling of the face, lips, tongue or throat, or difficulty breathing. Do the same for any severe or rapidly worsening symptom after an injection. If you have taken an unknown or excessive amount of anything sold as Cerebrolysin, call Poison Control at 1-800-222-1222. This page is not a substitute for a clinician who knows your history.
References (4 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Ziganshina LE, Abakumova T, Nurkhametova D et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026.Systematic reviewPMID 37818733full text
- 2.Muresanu DF, Heiss WD, Hoemberg V et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-9.Randomised trialPMID 26564102full text
- 3.Cui S, Chen N, Yang M et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11).Meta-analysisPMID 31710397full text
- 4.America's Poison Centers - confirms 1-800-222-1222 as the national Poison Control number, free and confidential, 24 hours a day.- America's Poison Centersother